24 May 2013
Keywords: gsk, tykerb, rival, herceptin, ph, iii, study
Article | 12 June 2006
UK drug major GlaxoSmithKline says that its investigational anticancer drug Tykerb (lapatinib ditosylate) increases life expectancy in breast
cancer patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 June 2006
29 May 2006
23 May 2013
© 2013 thepharmaletter.com